danuglipron

Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro
Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro
Stat
Pfizer
danuglipron
obesity
Wegovy
Mounjaro
Novo Nordisk
Flag link:
10 clinical trials to watch in the second half of 2023
10 clinical trials to watch in the second half of 2023
BioPharma Dive
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Flag link:
Pfizer Just Canned One of Its Ozempic Killers. What's Next?
Pfizer Just Canned One of Its Ozempic Killers. What's Next?
Motley Fool
Pfizer
obesity
lotiglipron
danuglipron
Novo Nordisk
Eli Lilly
Ozempic
Mounjaro
Flag link:
Obesity: Six trials to watch over the next 12 months
Obesity: Six trials to watch over the next 12 months
Clinical Trials Arena
obesity
clinical trials
Novo Nordisk
Altimmune
Innovent Biologics
Pfizer
Shionogi
Tonix
semaglutide
oxytocin
permvidutide
mazdutide
danuglipron
Flag link:
10 clinical trials to watch in the second half of 2023
10 clinical trials to watch in the second half of 2023
BioPharma Dive
FDA
clinical trials
Sarepta Therapeutics
Bridge Bio
Sanofi
Merck KGaA
Pfizer
Novo Nordisk
Verve Therapeutics
Roche
Vertex Pharmaceuticals
JNJ
Bristol Myers Squibb
ATTR-CM
Elevidys
tolebrutinib
evobrutinib
danuglipron
tiragolumab
VX-548
lazertinib
Flag link:
Pfizer, citing safety concerns, scraps one of two obesity pill hopefuls
Pfizer, citing safety concerns, scraps one of two obesity pill hopefuls
BioPharma Dive
Pfizer
obesity
lotiglipron
danuglipron
Flag link:
ADA 2023 preview – Lilly’s oral obesity data leave room for Pfizer
ADA 2023 preview – Lilly’s oral obesity data leave room for Pfizer
EP Vantage
ADA
Eli Lilly
Pfizer
diabetes
obesity
orforglipron
danuglipron
lotiglipron
Flag link:
Could Pfizer Have an Ozempic Killer on the Way?
Could Pfizer Have an Ozempic Killer on the Way?
Motley Fool
Pfizer
danuglipron
Novo Nordisk
Ozempic
weight loss
Flag link:
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss
Investors Business Daily
Pfizer
Novo Nordisk
weight loss
Ozempic
danuglipron
clinical trials
Flag link:
EASD 2022 – Pfizer’s oral GLP-1s struggle for a therapeutic window
EASD 2022 – Pfizer’s oral GLP-1s struggle for a therapeutic window
EP Vantage
Pfizer
EASD
danuglipron
diabetes
Flag link: